Drug intelligence / Profile preview

Regenfast

Development stage
Unknown
Lead developer
Mastelli
Modality
Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

Regenfast is a biomimetic combination hydrogel composed of polynucleotides (PN) and hyaluronic acid (HA). Developed by the Italian company Mastelli, it is specifically designed for use in oral and periodontal surgery to enhance wound healing, support soft-tissue repair, and promote bone regeneration. The polynucleotide component, derived from DNA fragments, acts as a precursor for nucleic acid synthesis and is thought to stimulate fibroblast activity and cell migration through the activation of adenosine A2A receptors. The hyaluronic acid component provides a scaffold for tissue growth, modulates early inflammatory responses, and creates an optimal microenvironment for healing. Regenfast is used as an adjunctive treatment in various procedures, including alveolar ridge preservation, sinus floor elevation, the management of intra-bony periodontal defects, and the treatment of medication-related osteonecrosis of the jaw (MRONJ).

Brand names
Regenfast
Other names
PN-HA gelPolynucleotides-Hyaluronic Acid GelPNHA gelPolynucleotide and Hyaluronic Acid-based Gel
02

Targets

ADORA2A (Adenosine A₂A Receptor)CD44 (CD44 antigen)

Beyond the preview

Go deeper on Regenfast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenfast.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call